Subconjunctival Bevacizumab injection on primary pterygium in Thammasat University Hospital: a randomized controlled trial
Woranart Tattiyakul*, Chunwarat Phattarapongdilok, Nattadet Rattana-aram
Department of Ophthalmology, Faculty of Medicine, Thammasat University, Thailand; E-mail:
Purpose: To evaluate the reduction in horizontal dimension of primary pterygium after subconjunctival Bevacizumab injection.
Materials and methods: Subjects with primary pterygium were randomized to study group (subconjunctival Bevacizumab injection group) and control group. The inclusion criteria were adults (age older than 18) with primary pterygium less than 3 millimeters in horizontal dimension. The primary outcome is the reduction of horizontal dimension at 1 week, 1 month, 3 months and 6 months.
Results: Fifty-nine subjects with primary pterygium were enrolled in this study. The mean age is 56.25 years (± 12.90). Forty-seven subjects were female, the remaining were male. Mean size reduction in the Bevacizumab group was 0.517 mm. (±0.301), 0.710 mm. (±0.359), and 0.790 mm. (±0.361) at 1 month, 3 months and 6 months respectively. Mean size reduction in control group was -0.067 mm. (±0.258), -0.010 mm. (±0.304) and -0.003 mm. (±0.366) at 1 month, 3 months, and 6 months respectively. The p-value of difference in pterygium size reduction between Bevacizumab group and control group is less than 0.001 at all visit.
Conclusion: The reduction of horizontal dimension in primary pterygium at 1 month, 3 months and 6 months is significantly greater in those who received subconjunctival bevacizumab injection compared to the control group.
Eye South East Asia ปี 2564, January-June ปีที่: 16 ฉบับที่ 1 หน้า 16-22
Randomized controlled trial, Primary pterygium, size reduction, subconjunctival bevacizumab injection